Amber Johnson1, Yekaterina B Khotskaya1, Lauren Brusco1, Jia Zeng1, Vijaykumar Holla1, Ann M Bailey1, Beate C Litzenburger1, Nora Sanchez1, Md Abu Shufean1, Sarina Piha-Paul2, Vivek Subbiah2, David Hong2, Mark Routbort3, Russell Broaddus4, Kenna R Mills Shaw1, Gordon B Mills1,5, John Mendelsohn1,6, Funda Meric-Bernstam1,2,7. 1. Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
PURPOSE: Precision oncology is hindered by the lack of decision support for determining the functional and therapeutic significance of genomic alterations in tumors and relevant clinically available options. To bridge this knowledge gap, we established a Precision Oncology Decision Support (PODS) team that provides annotations at the alteration-level and subsequently determined if clinical decision-making was influenced. METHODS: Genomic alterations were annotated to determine actionability based on a variant's known or potential functional and/or therapeutic significance. The medical records of a subset of patients annotated in 2015 were manually reviewed to assess trial enrollment. A web-based survey was implemented to capture the reasons why genotype-matched therapies were not pursued. RESULTS: PODS processed 1,669 requests for annotation of 4,084 alterations (2,254 unique) across 49 tumor types for 1,197 patients. 2,444 annotations for 669 patients included an actionable variant call: 32.5% actionable, 9.4% potentially, 29.7% unknown, 28.4% non-actionable. 66% of patients had at least one actionable/potentially actionable alteration. 20.6% (110/535) patients annotated enrolled on a genotype-matched trial. Trial enrolment was significantly higher for patients with actionable/potentially actionable alterations (92/333, 27.6%) than those with unknown (16/136, 11.8%) and non-actionable (2/66, 3%) alterations (p=0.00004). Actionable alterations in PTEN, PIK3CA, and ERBB2 most frequently led to enrollment on genotype-matched trials. Clinicians cited a variety of reasons why patients with actionable alterations did not enroll on trials. CONCLUSION: Over half of alterations annotated were of unknown significance or non-actionable. Physicians were more likely to enroll a patient on a genotype-matched trial when an annotation supported actionability. Future studies are needed to demonstrate the impact of decision support on trial enrollment and oncologic outcomes.
PURPOSE: Precision oncology is hindered by the lack of decision support for determining the functional and therapeutic significance of genomic alterations in tumors and relevant clinically available options. To bridge this knowledge gap, we established a Precision Oncology Decision Support (PODS) team that provides annotations at the alteration-level and subsequently determined if clinical decision-making was influenced. METHODS: Genomic alterations were annotated to determine actionability based on a variant's known or potential functional and/or therapeutic significance. The medical records of a subset of patients annotated in 2015 were manually reviewed to assess trial enrollment. A web-based survey was implemented to capture the reasons why genotype-matched therapies were not pursued. RESULTS: PODS processed 1,669 requests for annotation of 4,084 alterations (2,254 unique) across 49 tumor types for 1,197 patients. 2,444 annotations for 669 patients included an actionable variant call: 32.5% actionable, 9.4% potentially, 29.7% unknown, 28.4% non-actionable. 66% of patients had at least one actionable/potentially actionable alteration. 20.6% (110/535) patients annotated enrolled on a genotype-matched trial. Trial enrolment was significantly higher for patients with actionable/potentially actionable alterations (92/333, 27.6%) than those with unknown (16/136, 11.8%) and non-actionable (2/66, 3%) alterations (p=0.00004). Actionable alterations in PTEN, PIK3CA, and ERBB2 most frequently led to enrollment on genotype-matched trials. Clinicians cited a variety of reasons why patients with actionable alterations did not enroll on trials. CONCLUSION: Over half of alterations annotated were of unknown significance or non-actionable. Physicians were more likely to enroll a patient on a genotype-matched trial when an annotation supported actionability. Future studies are needed to demonstrate the impact of decision support on trial enrollment and oncologic outcomes.
Authors: Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock Journal: J Natl Cancer Inst Date: 2015-09-15 Impact factor: 13.506
Authors: Siân Jones; Valsamo Anagnostou; Karli Lytle; Sonya Parpart-Li; Monica Nesselbush; David R Riley; Manish Shukla; Bryan Chesnick; Maura Kadan; Eniko Papp; Kevin G Galens; Derek Murphy; Theresa Zhang; Lisa Kann; Mark Sausen; Samuel V Angiuoli; Luis A Diaz; Victor E Velculescu Journal: Sci Transl Med Date: 2015-04-15 Impact factor: 17.956
Authors: Funda Meric-Bernstam; Amber Johnson; Vijaykumar Holla; Ann Marie Bailey; Lauren Brusco; Ken Chen; Mark Routbort; Keyur P Patel; Jia Zeng; Scott Kopetz; Michael A Davies; Sarina A Piha-Paul; David S Hong; Agda Karina Eterovic; Apostolia M Tsimberidou; Russell Broaddus; Elmer V Bernstam; Kenna R Shaw; John Mendelsohn; Gordon B Mills Journal: J Natl Cancer Inst Date: 2015-04-11 Impact factor: 13.506
Authors: John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544
Authors: Geoffrey Kim; Amy E McKee; Yang-Min Ning; Maitreyee Hazarika; Marc Theoret; John R Johnson; Qiang Casey Xu; Shenghui Tang; Rajeshwari Sridhara; Xiaoping Jiang; Kun He; Donna Roscoe; W David McGuinn; Whitney S Helms; Anne Marie Russell; Sarah Pope Miksinski; Jeanne Fourie Zirkelbach; Justin Earp; Qi Liu; Amna Ibrahim; Robert Justice; Richard Pazdur Journal: Clin Cancer Res Date: 2014-08-05 Impact factor: 12.531
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway Journal: Nat Med Date: 2014-05-18 Impact factor: 53.440
Authors: Tira Tan; Michael Rheaume; Lisa Wang; Helen Chow; Anna Spreafico; Aaron R Hansen; Albiruni R A Razak; Lillian L Siu; Philippe L Bedard Journal: Oncologist Date: 2019-03-04
Authors: Nora S Sánchez; Michael P Kahle; Ann Marie Bailey; Chetna Wathoo; Kavitha Balaji; Mehmet Esat Demirhan; Dong Yang; Milind Javle; Ahmed Kaseb; Cathy Eng; Vivek Subbiah; Filip Janku; Victoria M Raymond; Richard B Lanman; Kenna R Mills Shaw; Funda Meric-Bernstam Journal: JCO Precis Oncol Date: 2019-09-24
Authors: Argun Akcakanat; Xiaofeng Zheng; Christian X Cruz Pico; Tae-Beom Kim; Ken Chen; Anil Korkut; Aysegul Sahin; Vijaykumar Holla; Emily Tarco; Gopal Singh; Senthil Damodaran; Gordon B Mills; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam Journal: Clin Cancer Res Date: 2021-03-29 Impact factor: 12.531
Authors: Michelle F Green; Jonathan L Bell; Christopher B Hubbard; Shannon J McCall; Matthew S McKinney; Jinny E Riedel; Carolyn S Menendez; James L Abbruzzese; John H Strickler; Michael B Datto Journal: JCO Precis Oncol Date: 2021-09-16
Authors: Jessica J Tao; Michael H Eubank; Alison M Schram; Nicholas Cangemi; Erika Pamer; Ezra Y Rosen; Nikolaus Schultz; Debyani Chakravarty; John Philip; Jaclyn F Hechtman; James J Harding; Lillian M Smyth; Komal L Jhaveri; Alexander Drilon; Marc Ladanyi; David B Solit; Ahmet Zehir; Michael F Berger; Peter D Stetson; Stuart M Gardos; David M Hyman Journal: JCO Precis Oncol Date: 2019-07-24